Program:
Overview of significant biological aspects presented during the meeting, including:

• Prediction of DMR/TFR
  • 01:17 Abstract S167: A novel immune-related score predicts deep molecular response in chronic-phase CML treated upfront with TKIs
  • 03:19 Abstract S166: A machine-learning approach identifies a 27-genes transcriptome signature predicting TFR in CML
  • 05:32 Abstract S169: A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and TFR in CML
• Outcome and treatment of blast crisis
  • 07: 14 Abstract S165: Development of a prognostic scroring system for CML in blast phase: Insights from the European LeukemiaNet Blast Phase Registry
  • 08:42 Abstract P706: Design and validation of mass cytometry apoptotic panel for predicting sensitivity of CML blast cells cross-resistant to TKIs to the BCL2 inhibitor venetoclax
  • 11:38 Abstract S168: Combinatory therapy of ponatinib and venetoclax was effective in the treatment of asciminib-resistant CML in vivo
• New therapeutic approaches
  • 12:29 Protac inhibitors of BCR::ABL1
  • 16:29 Potential for stem cell inhibition in CML
    
    
• Q&A Session

If you have any questions or comments to the speaker, please email info@cml-foundation.org.